Are patients with epithelial barrier disorders at higher
risk of skin complications?
There is no evidence that patients with barrier defects such as atopic
eczema have a higher risk for SARS-CoV-2 infection or skin complications
during COVID-19. However, patients with atopic dermatitis are often on
systemic immunosuppressants and should be monitored closely. Optimal
topical treatment regime should also be encouraged in all
patients.147